|
|
Post by sellhighdrinklow on Jun 18, 2021 22:35:30 GMT -5
To be honest I don't care who is there as long as they get some approved Technosphere drugs and sell them like crazy. What I would like is someone coming along like Jazz did with GWPH and giving us $200pps. A $200 buyout is a $50 BILLION price tag!!! That's not gonna happen!! That's your opinion. It could happen if things progress. |
|
|
|
Post by itellthefuture777 on Jun 24, 2021 10:05:29 GMT -5
$200 per share this is at least $4000 per share imo
|
|
|
|
Post by cedafuntennis on Jun 24, 2021 10:14:10 GMT -5
$200 per share this is at least $4000 per share imo You are very funny |
|
|
|
Post by mango on Jun 24, 2021 11:41:59 GMT -5
|
|
|
|
Post by nylefty on Jun 24, 2021 12:26:53 GMT -5
He was there last January, but as of now he's no longer listed on the RLS website and is no longer making announcements on behalf of RLS.
This reminds me of Kuka's fantasy about Hooper supposedly still working for Amgen after he joined MannKind's BOD. Hooper had resigned at Amgen but hadn't bothered to update his LinkedIn listing -- so Kuka insisted that Hooper was still at Amgen even though he had been scrubbed from the Amgen website. |
|
|
|
Post by nylefty on Jun 24, 2021 14:03:56 GMT -5
I emailed Mark Theeuwes, the President and CEO of RLs, asking whether Arthur Rubinfeld was still an officer or director at RLS and got this prompt answer:
2:29 PM (18 minutes ago)
to me
Interesting question and happy to help settle. Arthur is no longer the chairman of RLS, our website has the updated executive team and board. As the focus of the company shifted to FDA regulated pharmaceutical development, the board was augmented to add 2 accomplished MD’s in Orrin Devinsky (PI for GW’s phase 3 programs) and Steven Hoffman (PR on website). I do however consider Arthur a friend and continue to have dialogue with him as he is an accomplished business executive.
Hopefully that helps you,
Mark
|
|
|
|
Post by dh4mizzou on Jun 24, 2021 14:14:45 GMT -5
At this point my expectation is that anything RLS can contribute to MNKDs bottom line will be gravy.
|
|
|
|
Post by sayhey24 on Jun 24, 2021 14:23:29 GMT -5
I emailed Mark Theeuwes, the President and CEO of RLs, asking whether Arthur Rubinfeld was still an officer or director at RLS and got this prompt answer:
2:29 PM (18 minutes ago)
to me
Interesting question and happy to help settle. Arthur is no longer the chairman of RLS, our website has the updated executive team and board. As the focus of the company shifted to FDA regulated pharmaceutical development, the board was augmented to add 2 accomplished MD’s in Orrin Devinsky (PI for GW’s phase 3 programs) and Steven Hoffman (PR on website). I do however consider Arthur a friend and continue to have dialogue with him as he is an accomplished business executive.
Hopefully that helps you,
Mark
Great job - thanks for the answer. I thought Arthur was working to come up with a new Starbucks offering. When RLS announced they would have a recreational offering it was a bit surprising to me. The above answer makes perfect sense at this point. I am sure hoping RLS gets the FDA green light. Now that you are on a roll - how about finding out what happened with Dave Kendall. Why he left the easiest job he ever had is still a mystery. |
|
|
|
Post by mango on Jun 24, 2021 17:21:52 GMT -5
I emailed Mark Theeuwes, the President and CEO of RLs, asking whether Arthur Rubinfeld was still an officer or director at RLS and got this prompt answer:
2:29 PM (18 minutes ago)
to me
Interesting question and happy to help settle. Arthur is no longer the chairman of RLS, our website has the updated executive team and board. As the focus of the company shifted to FDA regulated pharmaceutical development, the board was augmented to add 2 accomplished MD’s in Orrin Devinsky (PI for GW’s phase 3 programs) and Steven Hoffman (PR on website). I do however consider Arthur a friend and continue to have dialogue with him as he is an accomplished business executive.
Hopefully that helps you,
Mark
Thanks for finding that out! Now all we need is that Phase 1 announcement from Receptor and we’re on our way! BTW—what email did you use to message him? Was it the info@receptorlife.com or something else? |
|
|
|
Post by nylefty on Jun 24, 2021 18:55:04 GMT -5
mtheeuwes@receptorlife.com
|
|
|
|
Post by prcgorman2 on Jun 28, 2021 6:20:59 GMT -5
It does seem RLS has some “life” in it. RLS is privately-held and progressing towards FDA approval and commercialization of products. Technosphere; the gift that keeps on giving. Go MNKD!
|
|
|
|
Post by mango on Jul 19, 2021 12:11:31 GMT -5
Next will be Cannabidiol Technosphere, folks! Receptor Life Sciences Announces Initiation of IND-Opening Clinical PK Study of RLS102 for Irritability in Autism Spectrum DisorderSEATTLE – Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for RLS102. This first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder. RLS102 is a novel formulation that uses an FDA-approved drug delivery technology. Following the IND acceptance, RLS initiated a pharmacokinetic (PK), formulation selection study using RLS102 in healthy volunteers. The results will be used to identify the formulation for clinical development. The RLS102 capsules contain both pure synthetic cannabidiol (CBD) and SNAC, an FDA-approved oral absorption enhancer. In an initial proof-of-concept clinical study, RLS102 resulted in a 6-fold increase in CBD absorption from the gastrointestinal tract compared to solid oral CBD alone. In addition to improving CBD bioavailability, RLS102 reduces the high variability associated with currently marketed oral CBD products. "RLS102 has the potential to be a new treatment to reduce irritability in patients living with autism spectrum disorder," said Mark Theeuwes, President and CEO, Receptor Life Sciences. "This IND acceptance is an important milestone for Receptor Life Sciences and demonstrates our ability to develop drug products in an FDA-regulated environment. We look forward to moving RLS102 into clinical efficacy studies as quickly as possible." A complex developmental disorder often associated with a high level of irritability, autism spectrum disorder (ASD) affects about 5 million adults in the United States (https://www.cdc.gov/ncbddd/autism/features/adults-living-with-autism-spectrum-disorder.html). No treatments are approved for adults with ASD-associated irritability. www.receptorlife.com/ |
|
|
|
Post by boca1girl on Jul 19, 2021 12:37:16 GMT -5
Next will be Cannabidiol Technosphere, folks! Receptor Life Sciences Announces Initiation of IND-Opening Clinical PK Study of RLS102 for Irritability in Autism Spectrum DisorderSEATTLE – Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for RLS102. This first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder. RLS102 is a novel formulation that uses an FDA-approved drug delivery technology. Following the IND acceptance, RLS initiated a pharmacokinetic (PK), formulation selection study using RLS102 in healthy volunteers. The results will be used to identify the formulation for clinical development. The RLS102 capsules contain both pure synthetic cannabidiol (CBD) and SNAC, an FDA-approved oral absorption enhancer. In an initial proof-of-concept clinical study, RLS102 resulted in a 6-fold increase in CBD absorption from the gastrointestinal tract compared to solid oral CBD alone. In addition to improving CBD bioavailability, RLS102 reduces the high variability associated with currently marketed oral CBD products. "RLS102 has the potential to be a new treatment to reduce irritability in patients living with autism spectrum disorder," said Mark Theeuwes, President and CEO, Receptor Life Sciences. "This IND acceptance is an important milestone for Receptor Life Sciences and demonstrates our ability to develop drug products in an FDA-regulated environment. We look forward to moving RLS102 into clinical efficacy studies as quickly as possible." A complex developmental disorder often associated with a high level of irritability, autism spectrum disorder (ASD) affects about 5 million adults in the United States (https://www.cdc.gov/ncbddd/autism/features/adults-living-with-autism-spectrum-disorder.html). No treatments are approved for adults with ASD-associated irritability. www.receptorlife.com/But this is an oral drug, not inhaled. What tells you they will follow with an inhaled version in this pr? |
|
|
|
Post by MnkdWASmyRtrmntPlan on Jul 19, 2021 13:24:22 GMT -5
But this is an oral drug, not inhaled.
Right, I'm also disappointed that it is synthetic (not natural), but I suppose that gets better consistency for pharmaceutical requirements.
That also makes it more understandable why this whole RLS thing is taking so long.
I doubt that developing a synthetic version of anything is very time-consuming.
And then setting up manufacturing for it is not a quick or easy process either.
Hopefully, the RLS team will be able to develop a QUICK turnaround process for inhalable versions to use for all their new drugs!!!
|
|
|
|
Post by mango on Jul 19, 2021 13:37:26 GMT -5
Next will be Cannabidiol Technosphere, folks! Receptor Life Sciences Announces Initiation of IND-Opening Clinical PK Study of RLS102 for Irritability in Autism Spectrum DisorderSEATTLE – Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for RLS102. This first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder. RLS102 is a novel formulation that uses an FDA-approved drug delivery technology. Following the IND acceptance, RLS initiated a pharmacokinetic (PK), formulation selection study using RLS102 in healthy volunteers. The results will be used to identify the formulation for clinical development. The RLS102 capsules contain both pure synthetic cannabidiol (CBD) and SNAC, an FDA-approved oral absorption enhancer. In an initial proof-of-concept clinical study, RLS102 resulted in a 6-fold increase in CBD absorption from the gastrointestinal tract compared to solid oral CBD alone. In addition to improving CBD bioavailability, RLS102 reduces the high variability associated with currently marketed oral CBD products. "RLS102 has the potential to be a new treatment to reduce irritability in patients living with autism spectrum disorder," said Mark Theeuwes, President and CEO, Receptor Life Sciences. "This IND acceptance is an important milestone for Receptor Life Sciences and demonstrates our ability to develop drug products in an FDA-regulated environment. We look forward to moving RLS102 into clinical efficacy studies as quickly as possible." A complex developmental disorder often associated with a high level of irritability, autism spectrum disorder (ASD) affects about 5 million adults in the United States (https://www.cdc.gov/ncbddd/autism/features/adults-living-with-autism-spectrum-disorder.html). No treatments are approved for adults with ASD-associated irritability. www.receptorlife.com/But this is an oral drug, not inhaled. What tells you they will follow with an inhaled version in this pr? Because Cannabidiol Technosphere is next in line in their pipeline and the only other product they have done presentations and studies on. |
|
